π£ New video!
Understanding HER2 testing in gynecological cancers
Prof. Fernando Soares provides a guideline-based overview πΊ
View/download the slides for more details: https://t.co/irOwaUTuwZ
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter #precisionmedicine
As HER2-targeted treatment options continue to expand in gynaecological cancers.
Prof. Fernando Soares provides practical guidance on HER2 IHC testing, scoring, and how HER2 status can inform treatment decisions.
#MedEd
β‘οΈ HER2 IHC testing is recommended in p53-aberrant endometrial carcinoma
β‘οΈ It may be considered in selected advanced/recurrent cervical & ovarian cancers when evaluating eligibility for HER2-targeted therapies
𧬠Find out more about #HER2 testing in gynecological cancers, best practice, & treatment selection
πΊ From Prof. Fernando Soares
Get the slides for more: https://t.co/aeqP7LQjSE
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter #precisionmedicine
β‘οΈ HER2 IHC testing is recommended in p53-aberrant endometrial carcinoma
β‘οΈ It may be considered in selected advanced/recurrent cervical & ovarian cancers when evaluating eligibility for HER2-targeted therapies
𧬠Find out more about #HER2 testing in gynecological cancers, best practice, & treatment selection
πΊ From Prof. Fernando Soares
Get the slides for more: https://t.co/irOwaUU2mx
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter #precisionmedicine
πΊ Endometrial cancer update from Prof. Domenica Lorusso
βοΈ Navigating recent ESGO guidelines
βοΈ Implications for clinical practice
What do HCPs need to know about treatment selection in advanced endometrial cancer?
πΊ Watch the video to find out!
View the slides: https://t.co/UB06f8978d
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #MedTwitter #endometrialcancer
Understanding HER2 testing in gynecological cancers: Best practices and treatment implications
βοΈ Get a guideline-driven overview of immunohistochemistry testing in endometrial, cervical & ovarian cancers
βοΈ Find out why accurate assessment is now critical for treatment selection
πΊ From Prof. Fernando Soares
Get the slides for more details: https://t.co/irOwaUU2mx
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter
Optimising treatment selection in advanced endometrial cancer
πΊ Expert video from Prof. Domenica Lorusso
Explore ESGO guidelines & what they mean for clinical practice
-Clinical relevance of molecular subtypes/their role in risk stratification & treatment planning
-Tx algorithms for advanced/recurrent disease, inc. distinctions between dMMR/non-dMMR tumours
-pembrolizumab + lenvatinib as a chemotherapy-free option for selected pts
-Established systemic treatment strategies across molecular subgroups
View the slides: https://t.co/UB06f8978d
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn #OncTwitter
Precision oncology in gynecological cancers β a MedEd programme for HCPs
πΊ Explore HER2 testing in endometrial, cervical & ovarian cancers
>> Guideline-based overview, best practice & treatment implications
w/ Prof. Fernando Soares
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
Precision oncology in gynecological cancers β a MedEd programme for HCPs
πΊ Explore HER2 testing in endometrial, cervical & ovarian cancers
>> Guideline-based overview, best practice & treatment implications
w/ Prof. Fernando Soares
https://t.co/irOwaUU2mx
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #OncTwitter #precisiononcology
HER2 testing is recommended in range of gynecological cancers.
Prof. Fernando Soares shares a practical, guideline-based overview of HER2 IHC testing and scoring across endometrial, cervical & ovarian cancers, and what it means for treatment selection.
π· Watch the full video here:
https://t.co/3O3weFXbo0
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #GynecologicOncology #PrecisionMedicine
Prof. Domenica Lorusso provides a concise, guideline-based overview of how molecular classification and clinical trial data inform treatment selection in advanced #endometrialcancer
πΊ Watch the video
View the slides: https://t.co/UB06f89EXL
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn
ESGO guidelines recommend ICI + chemotherapy followed by maintenance ICI Β± PARPi for advanced/recurrent non-dMMR (pMMR) #endometrialcancer
But what if chemotherapy is contraindicated?
Get an update on the ESGO guidelines and how they translate to clinical practice
πΊ Video from Prof. Domenica Lorusso
View the slides: https://t.co/UB06f89EXL
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn #endometrialcancer
We are delighted to receive a programme endorsement from the Gynecologic Oncology Trial and Investigation Consortium (GOTIC) once again.
Check out the programme β¬οΈ
Understanding HER2 testing in gynecological cancers: best practices and treatment implications >> https://t.co/aeqP7LQjSE
We greatly appreciate and value the longstanding collaboration with GOTIC over the past 7 years! We look forward to many more to come π€
Programme supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedicalEducation #precisionmedicine π·
Exploring best practice in HER2 testing in gynecological cancers
What are the guidelines around HER2 IHC testing & scoring in endometrial, cervical & ovarian cancers?
How does HER2 status impact treatment selection?
Prof. Fernando Soares answers these questions in a guideline-based overview
πΊ Video in this post
π Slides >> https://t.co/irOwaUTuwZ
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #OncTwitter #precisiononcology
πΊ Endometrial cancer update from Prof. Domenica Lorusso
βοΈ Navigating recent ESGO guidelines
βοΈ Implications for clinical practice
View the slides: https://t.co/UB06f89EXL
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn #endometrialcancer
Understanding HER2 testing in gynecological cancers: Best practices and treatment implications
- Get a guideline-driven overview of immunohistochemistry testing in endometrial, cervical & ovarian cancers
- Find out why accurate assessment is now critical for treatment selection
πΊ From Prof. Fernando Soares
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
π£ New video!
Understanding HER2 testing in gynecological cancers
Prof. Fernando Soares provides a guideline-based overview πΊ
View/download the slides for more details: https://t.co/irOwaUTuwZ
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter #precisionmedicine
β‘οΈ HER2 IHC testing is recommended in p53-aberrant endometrial carcinoma
β‘οΈ It may be considered in selected advanced/recurrent cervical & ovarian cancers when evaluating eligibility for HER2-targeted therapies
𧬠Find out more about #HER2 testing in gynecological cancers, best practice, & treatment selection
πΊ From Prof. Fernando Soares
Get the slides for more: https://t.co/irOwaUTuwZ
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter #precisionmedicine
Optimising treatment selection in advanced #endometrialcancer
Prof. Domenica Lorusso shares insights on how to navigate recent ESGO guidelines and the implications for clinical practice.
πΊ Video in this post!
View the slides: https://t.co/UB06f89EXL
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn #endometrial
You can review the latest ESGO guidelines for advanced endometrial cancer in one clear, evidence based resource based resource:
#GynecologicOncology#ESGO2026
Optimising treatment selection in advanced endometrial cancer
πΊ Expert video from Prof. Domenica Lorusso
Explore ESGO guidelines & what they mean for clinical practice
-Clinical relevance of molecular subtypes/their role in risk stratification & treatment planning
-Tx algorithms for advanced/recurrent disease, inc. distinctions between dMMR/non-dMMR tumours
-pembrolizumab + lenvatinib as a chemotherapy-free option for selected pts
-Established systemic treatment strategies across molecular subgroups
View the slides: https://t.co/UB06f8978d
π€ Programme endorsed by @WarOnCancer
Supported by an Independent Educational Grant from Eisai Europe Limited. Eisai Europe Limited has financially supported this activity and has had no influence on its creation or content
#MedEd #obgyn #OncTwitter
Understanding HER2 testing in gynecological cancers: Best practices and treatment implications
βοΈ Get a guideline-driven overview of immunohistochemistry testing in endometrial, cervical & ovarian cancers
βοΈ Find out why accurate assessment is now critical for treatment selection
πΊ From Prof. Fernando Soares
Get the slides for more details: https://t.co/irOwaUTuwZ
Supported by an Independent Educational Grant from Daiichi Sankyo. For HCPs only.
#MedEd #obgyn #MedTwitter